anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The overarching goal of the research plan is to test ways to leverage mobile technologies and social media to increase the impact, scalability, cost-effectiveness, and dissemination potential of lifestyle interventions that reduce cardiovascular disease (CVD) risk. Mobile technology and social media have the potential to reduce the intensity of traditional prevention interventions and enhance outcome by delivering behavioral strategies in-the-moment and by connecting patients other patients to generate better communication and a social support system for lifestyle changes.

This study includes a behavioral weight loss program delivered entirely via on online social network. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will be connected to one another via Facebook and receive behavioral counseling via posts from coaches who are present on the network daily. Participants will track their diet and exercise via a free commercial mobile app. Participants will be assigned to either a Facebook group allowing the invite of friends (wave 1), a Facebook group with open enrollment through week 8 (wave 2) or a Facebook group including only study participants. If they are assigned to the group including their friends, they have the opportunity to invite their friends to participate in the weight loss group if they are interested in losing weight as well. They will not have a limit as to how many friends they can invite. The friends that are invited will not undergo the same procedures as the Facebook (FB)+friends study participants, but we will provide them with a factsheet and collect minimal information from them. If they are assigned to the group with open enrollment through week 8, additional people will be recruited into that group. Those participants being enrolled between week 1-8 will undergo the same procedures as others besides randomization. The goal of both of these studies is to explore how to build the size of online weight loss groups in such a way that increases participant engagement. Feasibility outcomes include engagement (frequency of posts, likes, and comments and number of completed days of tracking posted) retention, acceptability, and weight loss. Post intervention focus groups will gather feedback on the program.
An isolated hepatitis C virus (HCV) NS5 protein (I) or its portion, where one or more cysteine thiol group being chemically or enzymatically modified in a reversible fashion, is new. Independent claims are also included for the following: (1) a composition (C1) comprising (I) or its portion and a carrier, adjuvant or vehicle; (2) determining (M1) the presence of HCV NS5 antigens in a biological sample, involves detecting HCV NS5 antigens with an antibody to the HCV NS5 antigens in the presence of (I) or its portion as competitor of binding of the HCV NS5 antigens to the antibody, where the detection is performed in the absence of a reducing agent; (3) a diagnostic kit for determining the presence of antibodies to HCV in a biological sample, for carrying out (M1), for determining the presence of an HCV virus in a biological sample or for diagnosing HCV infection in a mammal, comprising (I) or its portion; and (4) producing (I). ACTIVITY : Antiinflammatory; Hepatotropic; Virucide; Cytostatic. MECHANISM OF ACTION : Vaccine (claimed). In vivo analysis of the therapeutic effect of hepatitis C virus NS5 protein was carried out in mice as follows. The sulfonated protein (mTNF-H6-NS5A SO 3) and alkylated protein (mTNF-H6-NS5A iodoacetamide (IAA)) were diluted to 500 Microg/ml with sodium chloride (0.9%), mixed with an equal volume of Alhydrogel (1.3%) and finally further diluted with 8 volumes of sodium chloride (0.9%) to yield alum-adjuvanted NS5A at a concentration of 50 Microg NS5A/ml and Alhydrogel (0.13%). Groups of 6 Balb/c mice were immunized intramuscularly three times with a three-week interval with sulfonated or alkylated NS5A (5 Microg). The immune response was assessed 2 weeks after the third immunization. Antibody titers were determined by enzyme linked immunosorbent assay (ELISA). The result indicated presence of immune response against NS5A in all animals. Both the alkylated and the sulfonated protein induced a significant antibody response, which was detected by alkylated or desulfonated protein in the ELISA. Both the sulfonated and alkylated NS5A protein, were found to induce antibody response.
PURPOSE: A composition for prevention and treatment of dementia is provided to be used for preventing and treating frontotemporal demential which is inherited tau only dementia. CONSTITUTION: A composition for prevention and treatment of dementia includes a compound represented by chemical formula 1 as an active ingredient. The dementia is Alzheimer's dementia, and frontotemporal dementia or the Parkinson`s disease. The composition obstructs the tau hyperphosphorylated. The compound of the chemical formula 1 is administered in the concentration of 0.1-5 microM. The health supplement for the dementia prevention includes the compound of the chemical formula 1 as the active ingredient.
Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
<P>PROBLEM TO BE SOLVED: To obtain an IFN inducer by finding a substance to directly activate IRF-3 (Interferon Regulatory Factor) and to obtain a nucleic acid encoding the IFN inducer.  <P>SOLUTION: An RIG-I (Retinoic acid-inducible gene-I) variant for promoting production of interferon is obtained by constructionally activating an IRF group. The MDA-5 (Melanoma Differentiation Antigen-5) variant for promoting production of interferon is obtained by constructionally activating an IRF group. The nucleic acid encodes the RIG-I variant or the MDA-5 variant. The polypeptide functioning as the IFN inducer and the nucleic acid encoding the polypeptide are obtained for the first time by finding a substance to directly activate the IRF-3. Since administration of the polypeptide to an organism induces the production of IFNs in vivo, the peptide is useful for treating cancers, virus diseases or autoimmune diseases.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
* RELISTOR injection is for subcutaneous use only.
  * Single-dose pre-filled syringes: Do not remove the pre-filled syringe from the tray until ready to administer.
  * Inspect RELISTOR injection visually for particulate matter and discoloration prior to administration. RELISTOR injection is colorless to pale yellow. Discard the pre-filled syringe or vial if particulate matter or discoloration is present.
  * Administer RELISTOR injection subcutaneously in the upper arm, abdomen or thigh. Do not inject at the same spot each time (rotate injection sites).
  * RELISTOR single-dose vials: Once drawn into the syringe, if immediate administration is not possible, store at ambient room temperature and administer within 24 hours. Discard any unused portion that remains in the vial.
  * For patient or caregiver instructions for preparation and administration of RELISTOR injection (including recommended specifications for the syringe and needle to be used with the single-dose vial), see Instructions for Use.
A prepn. having good absorption property comprises a water-sol. substance (I) at a concn. exhibiting higher osmotic pressure than isotonic sodium chloride soln., a water-sol. cpd. (II) having chelating activity, and a medicine. Pref. (I) is 1 wt.% of more of a water-sol. salt (Ia) or 0.25 M or more of a water-sol. saccharide (Ib); (II) is a low mol. wt. cpd. (IIa) having one or more chelating ligand, or a macromolecular cpd. (IIb) having two or more chelating ligands; and the medicine has good water solubility, esp. it has a partition coefficient of 50 or less in chloroform/water. Also claimed is a prepn. having good absorption property comprising a water-sol. macromolecular cpd. having chelating activity (pref. (IIb)) and a medicine. Absorption of the medicine through the colon, rectum or vagina is promoted; thus medicines which are normally only poorly absorbed when given by this route can be administered effectively as suppositories, and a high concn. of the medicine in blood can be maintained for a long time.
INTRODUCTION: Behavioural weight loss programmes are generally accepted as being beneficial in reducing cardiometabolic risk and improving patient-reported outcomes. However, prospective data from large real-world cohorts are scarce concerning the mid-term and long-term impact of such interventions. The objective of this large prospective cohort study (n>10 000 participants) is to demonstrate the effectiveness of the standardised Nutritional and Psycho-Behavioural Rehabilitation programme (RNPC Programme) in reducing the percentage of subjects requiring insulin and/or other diabetes drug therapy, antihypertensive drugs, lipid-lowering therapies and continuous positive airway pressure therapy for obstructive sleep apnoea after the end of the intervention. The rate of remission of hypertension, type 2 diabetes and sleep apnoea will also be prospectively assessed.
METHODS: This is a prospective multicentre observational study carried out in 92 RNPC centres in France. Participants will follow the standardised RNPC Programme. The prospective dataset will include clinical, anthropometric and biochemical data, comorbidities, medications, body composition, patient-reported outcome questionnaire responses, sleep study data with objective measurements of sleep apnoea severity and surrogate markers of cardiovascular risk (ie, blood pressure and arterial stiffness). About 10 000 overweight or obese participants will be included over 2 years with a follow-up duration of up to 5 years.
ETHICS AND DISSEMINATION: Ethical approval for this study has been granted by the Ethics Committee (Comité de protection des personnes Sud-Est I) of Saint-Etienne University Hospital, France (SI number: 23.00174.000237). Results will be submitted for publication in peer-review journals, presented at conferences and inform the design of a future randomised controlled trial in the specific population identified as good responders to the RNPC Programme.
TRIAL REGISTRATION NUMBER: NCT05857319.
The objective of this study is to investigate the impact of melatonin on ischemic brain injury and elucidate its underlying molecular mechanism. In this investigation, a mouse model of middle cerebral artery occlusion (MCAO) was established using the thread occlusion method, followed by treatment with two different doses of melatonin: 5 mg/kg and 10 mg/kg. Additionally, HT-22 cells were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) and treated with varying concentrations of melatonin. The findings demonstrated that melatonin significantly reduced the extent of cerebral ischemia, nerve damage, brain edema, and neuronal apoptosis in MCAO mice. In vitro experiments further revealed that melatonin effectively enhanced cell proliferation while reducing cell apoptosis and reactive oxygen species (ROS) production following OGD/R treatment. Mechanistic investigations unveiled that melatonin exerted its protective effect by inhibiting ferroptosis through modulation of MDM2-mediated ubiquitination of ACSL4. In summary, this study suggests that melatonin regulates the MDM2/ACSL4 pathway to safeguard against ischemic brain injury, thereby providing novel therapeutic targets for such conditions.
The active ingredient in esomeprazole magnesium delayed-release capsules for oral administration is 1H-Benzimidazole,5-methoxy-2-[(S)-[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl], magnesium salt (2:1), a PPI. Esomeprazole is the S-isomer of omeprazole, which is a mixture of the S- and R- isomers. (Initial U.S. approval of esomeprazole magnesium: 2001). Its molecular formula is C34H36MgN6O6S2 with molecular weight of 713.12 on an anhydrous basis. The structural formula is:

The magnesium salt is an off-white to pale cream colored powder. It is slightly soluble in water. The stability of esomeprazole magnesium is a function of pH; it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions. At pH 6.8 (buffer), the half-life of the magnesium salt is about 19 hours at 25°C and about 8 hours at 37°C.

Esomeprazole magnesium is supplied in delayed-release capsules. Each esomeprazole magnesium delayed-release capsule contains 20 mg of esomeprazole (equivalent to 22.25 mg esomeprazole magnesium) or 40 mg of esomeprazole (equivalent to 44.50 mg esomeprazole magnesium) in the form of enteric-coated pellets with the following inactive ingredients: crospovidone, hydroxypropyl cellulose, mannitol, methacrylic acid-ethyl acrylate copolymer dispersion, sucrose, sugar spheres (corn starch and sucrose), talc, titanium dioxide and triethyl citrate. The capsule shells have the following inactive ingredients: gelatin and titanium dioxide, and may contain sodium lauryl sulfate. The imprinting ink contains black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
The botulinum toxin injection will be carried out by a doctor with experience in this therapeutic modality, which in turn is not part of the group of doctors who observe patients in the initial and subsequent phases. 100 Units (U) of botulinum toxin type A, in each lower limb (200 U in total), in muscle proximal thigh, once, at a moment that will be defined as T0. This group of 10 participans.
Cholesterol plays an important biological role in the body, and its disruption in homeostasis and synthesis has been implicated in several diseases. Mapping the locations of cholesterol is crucial for gaining a better understanding of these conditions. Silver deposition has proven to be an effective method for analyzing cholesterol using mass spectrometry imaging (MSI). We optimized and evaluated thermal evaporation as an alternative deposition technique to sputtering for silver deposition in MSI of cholesterol. A silver layer with a thickness of 6 nm provided an optimal combination of cholesterol signal intensity and mass resolution. The deposition of an ultrathin nanofilm of silver enabled high-resolution MSI with a pixel size of 10 μm. We used this optimized method to visualize the distribution of cholesterol in the senile plaques in the brains of APP/PS1 mice, a model that resembles Alzheimer's disease pathology. We found that cholesterol was evenly distributed across the frontal cortex tissue, with no evidence of plaque-like accumulation. Additionally, we investigated the presence and distribution of cholesterol in myocardial sections of a human heart affected by wild-type ATTR amyloidosis. We identified the presence of cholesterol in areas with amyloid deposition, but complete colocalization was not observed.
Before treatment, participants underwent routine blood and urine tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver and kidney function tests, tuberculous infection of T cells spot tests, hepatitis B virus marker tests, chest CT scans, etc. After exclusion of relevant contraindications, participants received subcutaneous ustekinumab therapy. During the treatment period, participants received ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg.
FIELD: medicine, surgery. SUBSTANCE: primary surgical treatment is carried out. It is performed extensive layer-by-layer infiltration of soft tissues along the periphery of wound under pressure. One should use ozonized physiological solution at 1.0-1.5 mg/l concentration at 1ml/1cm 3  tissue. True limits of tissue viability should be revealed and purulent-necrotic wound is resected within these limits. The method enables to decrease local hypoxia. EFFECT: higher efficiency of surgical treatment. 1 ex
PURPOSE: This study aimed to evaluate the ability of Kidney Stone Calculator (KSC), a flexible ureteroscopy surgical planning software, to predict the lithotripsy duration with both holmium:YAG (Ho:YAG) and thulium fiber laser (TFL).
METHODS: A multicenter prospective study was conducted from January 2020 to April 2023. Patients with kidney or ureteral stones confirmed at non-contrast computed tomography and treated by flexible ureteroscopy with laser lithotripsy were enrolled. "Kidney Stone Calculator" provided stone volume and subsequent lithotripsy duration estimation using three-dimensional segmentation of the stone on computed tomography and the graphical user interface for laser settings. The primary endpoint was the quantitative and qualitative comparison between estimated and effective lithotripsy durations. Secondary endpoints included subgroup analysis (Ho:YAG-TFL) of differences between estimated and effective lithotripsy durations and intraoperative outcomes. Multivariate analysis assessed the association between pre- and intraoperative variables and these differences according to laser source.
RESULTS: 89 patients were included in this study, 43 and 46 in Ho:YAG and TFL groups, respectively. No significant difference was found between estimated and effective lithotripsy durations (27.37 vs 28.36 min, p = 0.43) with a significant correlation (r =  + 0.89, p < 0.001). Among groups, this difference did not differ (p = 0.68 and 0.07, respectively), with a higher correlation between estimated and effective lithotripsy durations for TFL compared to Ho:YAG (r =  + 0.95, p < 0.001 vs r =  + 0.81, p < 0.001, respectively). At multivariate analysis, the difference was correlated with preoperative (volume > 2000 mm3 (Ho:YAG), 500-750 mm3 SV and calyceal diverticulum (TFL)), operative (fragmentation setting (p > 0.001), and basket utilization (p = 0.05) (Ho:YAG)) variables.
CONCLUSION: KSC is a reliable tool for predicting the lithotripsy duration estimation during flexible ureteroscopy for both Ho:YAG and TFL. However, some variables not including laser source may lead to underestimating this estimation.
Healthcare providers in intervention group T2 have the same condition as intervention group T1. Additionally they received on-site practical training to perform the assessment and can ask for support throughout the project concerning all aspects of oral health assessment and oral care.
This study will evaluate the 2-5 year outcome of a cohort of 250 patients with early synovitis, who were recruited into protocol 94-AR-0194 (The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis). Clinical, radiographic, and functional outcome parameters, particularly those relating to articular damage and functional loss, will be evaluated and related back to clinical, serologic, immunogenetic, and pathologic variables identified at the onset of the arthropathy. A model will be generated which incorporates and weighs the variables in order to determine diagnostic and prognostic markers in the early stages of arthritis. Synovial tissue samples have been obtained from the entire cohort at the initial visit of protocol 94-AR-0194. Studies of these biopsies have so far demonstrated evidence for the presence of infectious agents in a proportion of the samples, and have generated information regarding the cytokine profiles in the early stages of synovitis. In an attempt to further define the pathogenetic mechanisms of synovitis longitudinally, biopsies will be repeated on selected subsets of the cohort. Specific questions to be answered relate to the persistence of microbial agents in the synovium, and to the evolution of cellular and molecular mechanisms which mediate the invasive, destructive potential of the synovial lesion. It is anticipated that these studies should prove valuable to clinicians who are attempting to stratify patients for therapeutic strategies, early in their disease course. They should also prove valuable in enhancing the understanding of the pathogenetic mechanisms of synovitis.
A system and computer-implemented method for identifying fraudulent healthcare providers receives raw claims data from one or more data sources. The raw claims data includes claims associated with a selected healthcare provider. Each of the claims includes one or more claim lines. A first model is executed on the raw claims data. The first model determines a first score for the healthcare provider. A second model is executed on the raw claims data. The second model determines a second score for the healthcare provider. In addition, a third model is executed on the raw claims data. The third model determines a third score for the healthcare provider. A final provider-level risk score is determined for the healthcare provider based on the first, second, and third scores.
The invention concretely relates to a formula and a preparation method of a Hui Nationality traditional Chinese medicinal Agrimonia eupatoria esophagus cancer treatment granule. The granule is a green high-tech Chinese herbal medicine used for treating the esophagus cancer. The granule is a traditional Chinese medicinal granule prepared through the following steps: mixing of Agrimonia eupatoria, sal ammoniac, Chinese Sage Herb, Andrographis paniculata and other Chinese herbal medicines according to a certain ratio, water adding, decoction, extraction and concentration. The granule is mainly used for treating the esophagus cancer, and also is used for treating throat cancer, stomach cancer, colorectal cancer and other digestive system cancers. The granule has the characteristics of suitable medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers. The granule fundamentally improves the body functions and prevents and treats cancer cancerization at a low cost in order to recover the health of bodies.